Unlocking Q4 Potential of Abbott (ABT): Exploring Wall Street Estimates for Key Metrics

Core Viewpoint - Analysts project Abbott (ABT) will report quarterly earnings of $1.34 per share, a 12.6$11.02 billion, reflecting a 7.6% increase from the same quarter last year [1] Earnings Estimates - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a collective reevaluation by analysts [1][2] - Changes in earnings estimates are crucial for predicting investor reactions, as empirical research shows a strong correlation between earnings estimate revisions and short-term stock performance [2] Key Metrics Projections - Analysts estimate 'Net sales- Medical Devices- Rhythm Management- Total' at $623.50 million, a 7.1$1.82 billion, indicating a 17.3% increase from the prior-year quarter [4] - 'Net sales- Established Pharmaceuticals' is expected to be $1.31 billion, reflecting a 6.9$2.57 billion, a 1.4% increase from the prior-year quarter [5] - 'Net sales- Diagnostics- U.S.' is projected to be $1.03 billion, indicating a 0.9$1.54 billion, a 1.7% increase from the prior-year quarter [6] - 'Net sales- Nutrition- International' is expected to be $1.21 billion, reflecting a 3.1$942.92 million, indicating a 9.6% increase from the prior-year quarter [6] - 'Net sales- Medical Devices- Neuromodulation- International' is estimated at $50.56 million, a 17.6$303.63 million, reflecting a 6.5% increase [7] - 'Net sales- Medical Devices- Rhythm Management- International' is expected to reach $318.99 million, indicating a 7.4$279.89 million, reflecting a significant 21.2% increase year over year [8] Stock Performance - Abbott shares have shown a return of -0.7% over the past month, compared to the Zacks S&P 500 composite's -3.3% change, indicating relative outperformance [8]